Royalty Pharma plc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: RPRX-1 Category:


Royalty Pharma plc delivered mixed results for the previous quarter, with revenues below the analyst consensus. However, it managed to exceed Wall Street’s earnings expectations. The fiscal triumphs included a notable 9% augmentation in adjusted cash receipts, a parallel ascent in adjusted EBITDA, and a remarkable 10% surge in adjusted cash flow. A strategic highlight in capital allocation marked an active phase, with the acquisition of royalties amounting to an impressive $2.2 billion. The expanded partnership with PTC was particularly laudable, resulting in procuring additional royalties for Evrysdi, a treatment for spinal muscular atrophy. This transaction fortifies long-term growth and diversifies the portfolio, promising an attractive double-digit return. The narrative of success continued with a significant quarter in synthetic Royalty acquisitions, featuring transactions on two approved therapies, Skytrofa and Adstiladrin, totaling an outstanding $3.8 billion year-to-date, including upfront payments of $2.1 billion. Royalty Pharma’s commitment to maintaining an investment-grade credit rating, coupled with a capital structure boasting a long-duration, low-cost debt profile, positioned the company favorably. They also collaborated with Teva Pharmaceuticals International GmbH to expedite the clinical research program for Teva’s olanzapine LAI (TEV-‘749).

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!